Labcorp and PathAI Expand Digital Pathology Partnership
Labcorp is expanding its collaboration with PathAI to deploy an FDA-cleared digital pathology platform across the United States. The initiative aims to integrate AI-enabled diagnostics with LIMS and hospital data systems to increase throughput and improve audit trails. This move highlights a broader industry trend toward cloud-based, AI-driven platforms for managing complex lab data in regulated environments.
- This expanded partnership builds upon Labcorp's initial strategic investment in PathAI in 2019, which has since grown to include AI-supported clinical trials and the validation of new AI-based pathology solutions. - PathAI's AISight Dx platform is FDA-cleared and designed for interoperability, supporting various slide scanners from Leica, Hamamatsu, and Roche. This is a key feature, as Labcorp also recently announced a collaboration with Roche to implement its FDA-cleared digital slide scanners. - The deployment addresses a critical shortage of pathologists in the U.S., which is projected to be a shortfall of nearly 5,700 by 2030, by enabling more efficient, remote workflows and collaboration. - A significant feature of PathAI's platform is its ability to support biopharmaceutical partners in clinical trials by identifying specific biomarkers for more effective patient selection and stratification, accelerating drug development. - The global digital pathology market is projected to grow significantly, with some estimates suggesting it will reach over $3.5 billion by 2032, driven by the increasing adoption of AI and machine learning for more precise diagnostics. - PathAI's technology is designed to augment the work of human pathologists, not replace them, by using AI to analyze digital slide images for a more objective, data-driven analysis that can enhance accuracy and efficiency. - The AISight platform includes advanced features like "Z-Stack Image Support," which provides a 3D-like representation of tissue samples, particularly useful for complex cytology cases where cell clusters require layered analysis. - Integrating digital pathology platforms like AISight with existing Laboratory Information Management Systems (LIMS) is a major industry challenge; successful integration enables seamless data flow from image scanners to the LIS, automating workflows and reducing manual data handling.
